STHZ Stock Overview
StateHouse Holdings Inc. engages in the cultivation, processing, manufacturing, distribution, and retail of cannabis products for the adult-use and medical markets in the United States.
+ 1 more risk
StateHouse Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.21|
|52 Week High||CA$1.08|
|52 Week Low||CA$0.21|
|1 Month Change||-50.00%|
|3 Month Change||-43.24%|
|1 Year Change||-80.19%|
|3 Year Change||-88.40%|
|5 Year Change||n/a|
|Change since IPO||-95.92%|
Recent News & Updates
|STHZ||CA Pharmaceuticals||CA Market|
Return vs Industry: STHZ underperformed the Canadian Pharmaceuticals industry which returned -67.8% over the past year.
Return vs Market: STHZ underperformed the Canadian Market which returned -8.4% over the past year.
|STHZ Average Weekly Movement||19.5%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||18.1%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: STHZ is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: STHZ's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
StateHouse Holdings Inc. engages in the cultivation, processing, manufacturing, distribution, and retail of cannabis products for the adult-use and medical markets in the United States. It operates 14 dispensaries covering Northern and Southern California and one in Oregon. The company was formerly known as Harborside Inc. and changed its name to StateHouse Holdings Inc. in July 2022.
StateHouse Holdings Fundamentals Summary
|STHZ fundamental statistics|
Is STHZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STHZ income statement (TTM)|
|Cost of Revenue||US$52.73m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.19|
|Net Profit Margin||-57.89%|
How did STHZ perform over the long term?See historical performance and comparison
Is STHZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STHZ?
Other financial metrics that can be useful for relative valuation.
|What is STHZ's n/a Ratio?|
Price to Sales Ratio vs Peers
How does STHZ's PS Ratio compare to its peers?
|STHZ PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TILT TILT Holdings
VEXT Vext Science
STHZ StateHouse Holdings
Price-To-Sales vs Peers: STHZ is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does STHZ's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: STHZ is good value based on its Price-To-Sales Ratio (0.5x) compared to the Canadian Pharmaceuticals industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is STHZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.5x|
|Fair PS Ratio||7.3x|
Price-To-Sales vs Fair Ratio: STHZ is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (7.3x).
Share Price vs Fair Value
What is the Fair Price of STHZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate STHZ's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate STHZ's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is StateHouse Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if STHZ's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if STHZ's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if STHZ's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: STHZ's revenue (59% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: STHZ's revenue (59% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STHZ's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has StateHouse Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STHZ is currently unprofitable.
Growing Profit Margin: STHZ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STHZ is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare STHZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STHZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: STHZ has a negative Return on Equity (-47.11%), as it is currently unprofitable.
Discover strong past performing companies
How is StateHouse Holdings's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: STHZ's short term assets ($65.7M) do not cover its short term liabilities ($131.9M).
Long Term Liabilities: STHZ's short term assets ($65.7M) do not cover its long term liabilities ($158.1M).
Debt to Equity History and Analysis
Debt Level: STHZ's net debt to equity ratio (91.1%) is considered high.
Reducing Debt: STHZ's debt to equity ratio has reduced from 555.3% to 110.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STHZ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: STHZ has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 5.6% each year.
Discover healthy companies
What is StateHouse Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|StateHouse Holdings Dividend Yield vs Market|
|Company (StateHouse Holdings)||n/a|
|Market Bottom 25% (CA)||2.1%|
|Market Top 25% (CA)||6.1%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (StateHouse Holdings)||n/a|
Notable Dividend: Unable to evaluate STHZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STHZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STHZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STHZ's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STHZ has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
StateHouse Holdings has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: STHZ insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|30 Jun 22||BuyCA$7,406||Thomas DiGiovanni||Individual||20,000||CA$0.37|
|22 Jun 22||BuyCA$7,761||Thomas DiGiovanni||Individual||20,000||CA$0.39|
|16 Jun 22||BuyCA$2,446||Edward Schmults||Individual||6,000||CA$0.41|
|02 Jun 22||BuyCA$119,169||Andrew Sturner||Individual||227,000||CA$0.60|
|29 Apr 22||BuyCA$6,710,992||Entourage Effect Capital, LLC||Company||14,960,957||CA$0.45|
|01 Mar 22||BuyCA$4,998,980||Entourage Effect Capital, LLC||Company||4,158,890||CA$1.20|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 207.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
StateHouse Holdings Inc.'s employee growth, exchange listings and data sources
- Name: StateHouse Holdings Inc.
- Ticker: STHZ
- Exchange: CNSX
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$53.004m
- Shares outstanding: 252.40m
- Website: https://www.statehouseholdings.com
- StateHouse Holdings Inc.
- 1295 West Morena Blvd
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STHZ.F||OTCPK (Pink Sheets LLC)||Yes||Subordinate Voting Shares||US||USD||Jun 2019|
|STHZ||CNSX (Canadian National Stock Exchange)||Yes||Subordinate Voting Shares||CA||CAD||Jun 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.